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Chronic respiratory infection, predominantly with Pseudomot~s aeruginosa, is the 
most important cause of morbidity and mortality in Cystic Fibrosis. Staphylococcus 
aureus is a pathogen with significant impact for CF although its cl inical 
management remains controversial. 
We report some cases of cbronic airway colonizat ion with glycopeptide 
intermediate susceptibility Staphylococcus aureus (GISA). 
Detection of GISA was screened in parallel for vancomycin and teicoplanin 
susceptibility, by E test performed with high (2.0 Mc Far land) incculum on brain 
heart ilffusion (BHI). E test MICs was performed at standard (0.5 Mc Farland) 
incculum on Muel ler t t inton agarose (MHA).  Population was analyzed without or 
after vancomycin induction. 
Of  167 isolates, 43 (25.75%) were methici l l in resistant S. aureus (MRSA) and 6 
(3.6%) were GISA. Of  6 GISA, 4 isolates were MRSA gent amicin resistant, 1 was 
MRSA gentamicin susceptible and 1 was MSSA gentamicin susceptible. Two 
GISA were resistant o rifampicin and 2 to fosfomycin as determined by disk 
diffusion. Only 3 patients received teicoplanin. Genotyping using pulsed field gel 
electr ophoresis (PFGE) of GISA isolates allowed identification of several clones. 
Risk for acquisition of GISA is probably outweighed and strict surveil lance for the 
emergence of these strains should be recommended. 
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Aims:  We have developed different l iposomal formulations with the aim of 
improving bactericidal efficacy of aminoglycosides and macrolides against cl inical 
strains of /~ aerugbgpsa isolated from cystic fibrosis patients. Methods: 
Aminoglycosides and macr olides antibiotics were incorporated into liposomes. The 
sizes and the encapsulation efficiencies were determined. The stability of these 
liposomal formulations was evaluated both in buffer and in plasma. The MICs of 
free and liposomal antibiotics for/~ aeruginosa were assessed by uti l iz ing a broth 
dilution technique. The mechanism of bacterial interaction with these vesicles was 
monitored by transmission electron microscopy (TEM) and conf irmed by 
fluorescence activated cell sorting (FACS) analysis and lipid mixing assay. Results: 
The average liposomal size was found to be 2CQ nm. The encapsulation efficiency 
of liposomes~entrapped amikacin, gentamicin, tobramycin or erytbromycin was 
29.3 + 1.2%; 33 + 0.8%; 22.3 + 1.5%; 32.1 + 0.8 % of initial amount of the drugs 
in solution respectively. The encapsulation of aminoglycosides and macrolides into 
liposomes ignificantly enhanced ti le in-vitro antibacterial ctivity of these agents 
against cl inical resistant strains of /~ aeruginosa. TEM revealed that liposomes 
interact very closely with the outer membrane of/~ aeruginosa leading to bacterial 
membrane deformation suggesting that our liposomes fuse with outer membrane of 
t~ aeruginosa. This fusion between liposomes and the outer membrane /~ 
aeruginosa was confirmed by FACS analysis and lipid mixing assay. Conclusion: 
these data indicate that the l iposome formulations tested could be more ffective 
than the free drags in the management of pulmonary infections caused by /~ 
aeruginosa. 
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Inr  reduct ion S aureus is common in young CF children, and early work suggested 
that prophylactic therapy was beneficial (< 2 years of age). However, file need for 
prophylaxis in older children and adult patients i unclear. To assess current 
prophylactic practice, we  surveyed aproportion of both paediatric and adult UK  CF 
clinics. 
Methods The survey included questions on the incidence of S aureus, the presence 
of protccols for anti siaphylcccccal prophylaxis, up to what age such therapy was 
given, which drugs were used, and whether they were continued when chronic P 
aeruginosa infection ensued or azithr omycin therapy commenced. 
Results Of 28 centres urveyed (16 adult, 12 paediatric) more paediatric than adult 
clinics stated it was common to grow S aureus (3/12 versus 2/16). 11 (39%) had 
pr ot ccols for prophylaxis, mainly at paediatric units (9, 75%). Al l  used prophylaxis, 
12 (43%) from birth or diagnosis, and the remainder on transfer from elsewhere. 
Although most clinics continued prophylaxis, 2 gave it to the age of 2 years only, 
and 1 to the age of 12. The drug of choice in 24 (86%) was flucloxacill in, 1 (4%) 
cephradine, and 3 (10%) a mixture of agents. 5 (18%) stopped this therapy i f  
chronic P aeruginosa infection occunced, but only 8 (29%) when azithromycin 
therapy was instituted, despite its anti st aphylcccccal activity. 
Conclusions This survey has shown that although most units in the UK administer 
anti staphylcccccal prophylaxis to CF patients, many do not have protccols for its 
use and there is great variation in the duration of treatment. Furthermore, many 
continue its use when azithromycin is also administered, obviating a rational 
prescribing approach. Prophylaxis is also given to adult patients, increasing the 
treatment burden when there is no proven benefit. 
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Aims. To compare Pseudomot~s aeruginosa (PA) antibiotic resistance rates in 
chi ldren with CF receiving elect ive IV  antibiotic regimen (preference for 
monotherapy and Ceftazidime yt choice) (1) at periods 10 years apart and (2) with 
rescue antibiotics (oral ciprofloxacin or combination IV antibiotics) in the same 
t ime period. 
Methods. Antibiotic resistance rates of PA isolated from sputum of chi ldren with 
CF receiving elective IV antibiotics in file fkst quarter of 2004 (2CO4A, 129 
patients) were compared with (1) 1994 (1994A, 120 patients) and (2) patients 
receiving rescue antibiotics (oral ciprofloxacin or combination IV antibiotics) in 
2CO4 (2CO4B, 71 patients). Patients attended a single tertiary centre. Modif ied 
Stokes' method was used to test in vitro susceptibility. 
Results. Rates of PA, Cettazidime resistant PA (Table) and multiply resistant PA 
(resistance to >2 antibiotic groups) in 2CO4A did not differ from 1994A or 2CO4B. 
PA resistance rates % 2004A 1994A 2004B P 
Ce fta21dime 37 32 31 0.6 
Tobrarnycin 17 90 17 0.6 
Colisfin 8 1 7 0.6 
Meropenem 40* 12" 41 <0.001" 
Ciprofloxacin ")3** ")9 52** 0.007** 
Conclusion. Except for meropenem which was the 2 ~d choice antibiotic in 2004 but 
not in 1994, PA resistance rates did not significantly increase in this 10 year period 
despite an elective IV antibiotic treatment s rategy and preference for monother apy, 
in the children with CF. PA resistance rates and multiple resistance rates were not 
significantly higher in patients receiving elective IV antibiotics compared to those 
on rescue treatment in 2CO4. The routine use of ciprofloxacin in the latter was 
asscciated with an increased rate of ciprofloxacin resistant PA. 
